Cargando…

Strikingly poor CD8(+) T cell immunogenicity of vaccinia virus strain MVA in BALB/c mice

Vaccinia virus (VACV) strain MVA is a highly attenuated vector for vaccines that is being explored in clinical trials. We compared the CD8(+) T cell immunogenicity of MVA with that of a virulent laboratory strain of VACV (strain WR) in BALB/c mice by examining epitope-specific responses as well as e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russell, Tiffany A., Tscharke, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037371/ https://www.ncbi.nlm.nih.gov/pubmed/24566805 http://dx.doi.org/10.1038/icb.2014.10

Ejemplares similares

CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice
por: Veit, Svenja, et al.
Publicado: (2018)

A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice
por: Kalodimou, Georgia, et al.
Publicado: (2019)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Surprisingly Effective Priming of CD8(+) T Cells by Heat-Inactivated Vaccinia Virus Virions
por: Croft, Sarah, et al.
Publicado: (2020)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
por: Pérez, Patricia, et al.
Publicado: (2020)

Effect of the Route of Administration of the Vaccinia Virus Strain LIVP to Mice on Its Virulence and Immunogenicity
por: Shchelkunov, Sergei N., et al.
Publicado: (2020)

Effect of Serial Passage on the Pathogenicity and Immunogenicity of Vaccinia Virus LC16m8 Strain
por: Eto, Akiko, et al.
Publicado: (2021)

Enhancing the Immunogenicity of Vaccinia Virus
por: Shchelkunov, Sergei N., et al.
Publicado: (2022)

Can vaccinia virus be replaced by MVA virus for testing virucidal activity of chemical disinfectants?
por: Rabenau, Holger F, et al.
Publicado: (2010)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Nave, Lior, et al.
Publicado: (2023)

Genes that Control Vaccinia Virus Immunogenicity
por: Shchelkunov, S. N., et al.
Publicado: (2020)

Immunodomination during Peripheral Vaccinia Virus Infection
por: Lin, Leon C. W., et al.
Publicado: (2013)

Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression
por: Q. Marín, María, et al.
Publicado: (2018)

Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate
por: Currier, Jeffrey R., et al.
Publicado: (2010)

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees
por: Nilsson, C, et al.
Publicado: (2009)

Modified Vaccinia Virus Ankara Can Induce Optimal CD8(+) T Cell Responses to Directly Primed Antigens Depending on Vaccine Design
por: Wong, Yik Chun, et al.
Publicado: (2019)

Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
por: Goossens, Martine, et al.
Publicado: (2013)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified Vaccinia virus Ankara (MVA)
por: Marcacci, Maurilia, et al.
Publicado: (2020)

Diversity of cell death signaling pathways in macrophages upon infection with modified vaccinia virus Ankara (MVA)
por: Klaas, Lioba, et al.
Publicado: (2021)

Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
por: Alharbi, Naif Khalaf, et al.
Publicado: (2022)

Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain
por: Bissa, Massimiliano, et al.
Publicado: (2013)

Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
por: Cottingham, Matthew G., et al.
Publicado: (2008)

Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE(®) against aerosolized rabbitpox virus in a rabbit model()
por: Garza, Nicole L., et al.
Publicado: (2009)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
por: Altenburg, Arwen F., et al.
Publicado: (2014)

Potent CD8(+) T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1
por: Berthoud, Tamara K., et al.
Publicado: (2011)

Adaptive Immune Response to Vaccinia Virus LIVP Infection of BALB/c Mice and Protection against Lethal Reinfection with Cowpox Virus
por: Shchelkunov, Sergei N., et al.
Publicado: (2021)

Immunogenicity of SARS inactivated vaccine in BALB/c mice
por: Xiong, Sheng, et al.
Publicado: (2004)

Immunogenicity Assessment of Rift Valley Fever Virus Virus-Like Particles in BALB/c Mice
por: Li, Yuetao, et al.
Publicado: (2020)

Effect of the ati Gene Deletion on the Pathogenicity and Immunogenicity of the Vaccinia Virus
por: Yakubitskiy, S. N., et al.
Publicado: (2023)

The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host
por: Calvo-Pinilla, Eva, et al.
Publicado: (2018)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
por: Cottingham, Matthew G., et al.
Publicado: (2011)

Protection of IFNAR (−/−) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2
por: Jabbar, Tamara Kusay, et al.
Publicado: (2013)

High Quality Long-Term CD4(+) and CD8(+) Effector Memory Populations Stimulated by DNA-LACK/MVA-LACK Regimen in Leishmania major BALB/c Model of Infection
por: Sánchez-Sampedro, Lucas, et al.
Publicado: (2012)

Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy
por: Sumner, Rebecca P., et al.
Publicado: (2013)

Immunogenicity of RSV F DNA Vaccine in BALB/c Mice
por: Eroglu, Erdal, et al.
Publicado: (2016)

A Deleted Deletion Site in a New Vector Strain and Exceptional Genomic Stability of Plaque-Purified Modified Vaccinia Ankara (MVA)
por: Jordan, Ingo, et al.
Publicado: (2019)

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects
por: Frey, Sharon E., et al.
Publicado: (2015)

Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators
por: Sumner, Rebecca P., et al.
Publicado: (2016)

Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA)
por: Chiam, Rachael, et al.
Publicado: (2009)

Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells
por: Peng, Chen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_abhu84no906n2rt0o37an5icl3